Personalized cancer vaccines and their integration with standard of care modalities
Cancer Treatment Reviews · 2026-02 · 143 · 103095
DOI: 10.1016/j.ctrv.2026.103095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-02. Verfasst von Tiia Snäkä und 6 weiteren Autor:innen. Beteiligte Einrichtung: Swiss Medical Network, Clinique de Genolier, Genolier, Switzerland. Hauptthemen laut MEDLINE: Cancer Vaccines, Precision Medicine, Neoplasms, Standard of Care. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben.
Abstract (Originalsprache)
Cancer vaccines have matured significantly with advances in antigen discovery, delivery platforms, and personalized design driven by breakthroughs in genomics and artificial intelligence - yet they remain underutilized in clinical oncology. A growing body of evidence now demonstrates that the key to unlocking their full potential lies not in using them in isolation, but in strategically combining them with other treatment modalities. Vaccines exert their greatest efficacy when administered during defined immunologic windows-periods in which the patient's immune system is most amenable to activation and durable antigen-specific priming. Crucially, combination with standard-of-care (SOC) therapies such as chemotherapy, radiotherapy, and immune checkpoint inhibitors can generate synergistic effects that reshape the tumor-immune interface. Cytotoxic and targeted agents can enhance antigen release, modulate the tumor microenvironment, and promote immune infiltration, thereby creating a more permissive milieu for vaccine-induced responses. In reciprocity, vaccination can potentiate the efficacy of SOC regimens by amplifying tumor-specific immunity, counteracting resistance mechanisms, and sustaining immune surveillance. Thus, the emerging paradigm positions cancer vaccines not as standalone interventions, but as integral components of a multimodal therapeutic architecture. Strategic co-deployment of vaccines within SOC frameworks represents a scientifically grounded and clinically actionable approach to achieving durable tumor control and long-term remission in patients with solid malignancies. This review delineates the mechanistic rationale and clinical evidence supporting such integration across the continuum of disease stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Swiss Medical Network, Clinique de Genolier, Genolier, Switzerland.
- Swiss Medical Network, Clinique Générale-Beaulieu, Geneva, Switzerland.
- Swiss Medical Network, Clinique de Genolier, Genolier, Switzerland; Swiss Medical Network, Clinique Générale-Beaulieu, Geneva, Switzerland.
- Swiss Medical Network, Clinique de Genolier, Genolier, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland; Department of Oncology, University of Lausanne, Lausanne, Switzerl…
Zitieren
APA
Snäkä, T., Friedlaender, A., Graciotti, M., Hernandez, M., Rossier, L., Kirchner, V., & Kandalaft, L. (2026). Personalized cancer vaccines and their integration with standard of care modalities. Cancer Treatment Reviews, 143, 103095. https://doi.org/10.1016/j.ctrv.2026.103095
Vancouver
Snäkä T, Friedlaender A, Graciotti M, Hernandez M, Rossier L, Kirchner V, et al. Personalized cancer vaccines and their integration with standard of care modalities. Cancer Treatment Reviews. 2026;143:103095. doi:10.1016/j.ctrv.2026.103095
BibTeX
@article{Snk2026,
author = {Snäkä, Tiia and Friedlaender, Alex and Graciotti, Michele and Hernandez, Miriam and Rossier, Laetitia and Kirchner, Volker and Kandalaft, Lana},
title = {Personalized cancer vaccines and their integration with standard of care modalities},
journal = {Cancer Treatment Reviews},
year = {2026},
volume = {143},
pages = {103095},
doi = {10.1016/j.ctrv.2026.103095}
}
EUVIMED